![Anja Harmeier](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Anja Harmeier
Directeur Général chez
ReWind Therapeutics NV
Profil
Anja Harmeier is Chief Executive Officer at ReWind Therapeutics NV since 2021.
Also holds the position of Director at uniQure France SAS. Serves as Head-Roche Venture Fund at Roche Ventures since 2017.
Former roles include Director at Zikani Therapeutics, Inc., Minoryx Therapeutics SL, Entrada Therapeutics, Inc., and Vico Therapeutics BV.
Partner at Pureos Partners AG from 2020 to 2022.
Education includes an MBA from Instituto de Empresa SL in 2015 and a doctorate from Freie Universität Berlin in 2008.
Postes actifs de Anja Harmeier
| Sociétés | Poste | Début |
|---|---|---|
Roche Ventures
 Roche Ventures Investment ManagersFinance Roche Ventures invests in companies located in Switzerland and the United States. The firm focuses on pharmaceuticals, diagnostics and digital health. It participates in early stage capital transactions with an investment size of CHF 3 - 10 million. It acquires minority stakes and also makes follow-on financing. | Private Equity Investor | 01/03/2017 |
Corlieve Therapeutics SAS
 Corlieve Therapeutics SAS Pharmaceuticals: MajorHealth Technology Develops transformational medicines for neurological diseases | Directeur/Membre du Conseil | - |
ReWind Therapeutics NV
 ReWind Therapeutics NV Pharmaceuticals: MajorHealth Technology Develops novel re-myelinating therapies | Directeur Général | 22/09/2021 |
Anciens postes connus de Anja Harmeier
| Sociétés | Poste | Fin |
|---|---|---|
Pureos Partners AG
 Pureos Partners AG Investment ManagersFinance Pureos Partners invests in companies located in Switzerland. The firm focuses on drug development companies. It participates in early stage capital transactions. | Private Equity Investor | 31/08/2022 |
Vico Therapeutics BV
 Vico Therapeutics BV BiotechnologyHealth Technology Develops ribonucleic acid modulating therapies | Directeur/Membre du Conseil | - |
Minoryx Therapeutics SL
 Minoryx Therapeutics SL BiotechnologyHealth Technology Develops pharmaceutical products | Directeur/Membre du Conseil | - |
| ENTRADA THERAPEUTICS, INC. | Directeur/Membre du Conseil | - |
Zikani Therapeutics, Inc.
 Zikani Therapeutics, Inc. Drugstore ChainsRetail Trade Focuses on the discovery and development of novel macrolide antibiotics for the treatment of life-threatening bacterial infections caused by drug resistant pathogens | Directeur/Membre du Conseil | - |
Formation de Anja Harmeier
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
17
Relations au 1er degré
10
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 10 |
|---|---|
Zikani Therapeutics, Inc.
Zikani Therapeutics, Inc. Drugstore ChainsRetail Trade Focuses on the discovery and development of novel macrolide antibiotics for the treatment of life-threatening bacterial infections caused by drug resistant pathogens | Retail Trade |
Roche Ventures
Roche Ventures Investment ManagersFinance Roche Ventures invests in companies located in Switzerland and the United States. The firm focuses on pharmaceuticals, diagnostics and digital health. It participates in early stage capital transactions with an investment size of CHF 3 - 10 million. It acquires minority stakes and also makes follow-on financing. | Finance |
Instituto de Empresa SL
 Instituto de Empresa SL Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Freie Universität Berlin
 Freie Universität Berlin Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Minoryx Therapeutics SL
Minoryx Therapeutics SL BiotechnologyHealth Technology Develops pharmaceutical products | Health Technology |
ReWind Therapeutics NV
ReWind Therapeutics NV Pharmaceuticals: MajorHealth Technology Develops novel re-myelinating therapies | Health Technology |
Pureos Partners AG
Pureos Partners AG Investment ManagersFinance Pureos Partners invests in companies located in Switzerland. The firm focuses on drug development companies. It participates in early stage capital transactions. | Finance |
Entrada Therapeutics, Inc.
 Entrada Therapeutics, Inc. BiotechnologyHealth Technology Develops therapeutics for rare neuromuscular diseases | Health Technology |
Vico Therapeutics BV
Vico Therapeutics BV BiotechnologyHealth Technology Develops ribonucleic acid modulating therapies | Health Technology |
Corlieve Therapeutics SAS
Corlieve Therapeutics SAS Pharmaceuticals: MajorHealth Technology Develops transformational medicines for neurological diseases | Health Technology |
Choisissez Zonebourse 
